Boston Life Sciences (US) files for Parkinson's agent:
This article was originally published in Clinica
Boston Life Sciences (US) plans to begin a clinical trial with the Parkinson's disease radioimaging agent, Altropane, before the end of this year. An IND (investigational new drug) application has been filed with the FDA. The radiolabelled molecule binds to the dopamine transporter in areas of the brain affected by the disease. Use of Altropane is expected to provide earlier diagnosis of Parkinson's, enabling earlier therapeutic intervention, says chief scientific officer Marc Lanser. Apart from later-stage products obtained through the merger with Greenwich Pharmaceuticals, Altropane is Boston Life Sciences' first product to enter clinical development.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.